Systemic leukotriene B4 receptor antagonism lowers arterial blood pressure and improves autonomic function in the spontaneously hypertensive rat.
Paul J MarvarEmma B HendyThomas D CruiseDawid WalasDanielle DeCiccoRajanikanth VadigepalliJames S SchwaberHidefumi WakiDavid MurphyJulian F R PatonPublished in: The Journal of physiology (2016)
Accumulating evidence indicates an association between hypertension and chronic systemic inflammation in both human hypertension and experimental animal models. Previous studies in the spontaneously hypertensive rat (SHR) support a role for leukotriene B4 (LTB4 ), a potent chemoattractant involved in the inflammatory response. However, the mechanism for LTB4 -mediated inflammation in hypertension is poorly understood. Here we report in the SHR, increased brainstem infiltration of T cells and macrophages plus gene expression profiling data showing that LTB4 production, degradation and downstream signalling in the brainstem of the SHR are dynamically regulated during hypertension. Chronic blockade of the LTB4 receptor 1 (BLT1) receptor with CP-105,696, reduced arterial pressure in the SHR compared to the normotensive control and this reduction was associated with a significant decrease in low and high frequency spectra of systolic blood pressure, and an increase in spontaneous baroreceptor reflex gain (sBRG). These data provide new evidence for the role of LTB4 as an important neuro-immune pathway in the development of hypertension and therefore may serve as a novel therapeutic target for the treatment of neurogenic hypertension.
Keyphrases
- blood pressure
- hypertensive patients
- heart rate
- high frequency
- inflammatory response
- oxidative stress
- genome wide
- transcranial magnetic stimulation
- endothelial cells
- spinal cord injury
- molecular dynamics
- smoking cessation
- anti inflammatory
- drug induced
- artificial intelligence
- pluripotent stem cells
- replacement therapy
- data analysis